Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Coronavirus Notebook: G7 Agree On ‘Clinical Trial Charter’, Regulators Focus On Real World Data

Executive Summary

The European Medicines Agency has issued advice on managing thrombosis with thrombocytopenia syndrome (TTS) in people vaccinated with adenovirus vaccines, and Brazil has OKd the import of Sputnik V and Covaxin, albeit with numerous strings attached.

You may also be interested in...



COVID-19: EMA Says Guillain-Barré Syndrome Is A Side-Effect Of AZ’s Vaxzevria

The EU’s pharmacovigilance committee has recommended safety updates for two COVID-19 vaccines, and is keeping its eye on a range of possible side-effects with all four authorized products.

Will COVID Finally Help US FDA And Sponsors Overcome Their ‘Angst’ On Innovative Trial Designs?

The ‘sea change’ inside White Oak should be seen as very encouraging for sponsors, FDA official says.

Pandemic ‘Roadmap’ Will Show How To Develop New Vaccines in 100 Days

The pharmaceutical industry is a key player in a new partnership that aims to bring the public and private sectors together to address future complex health threats.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS144442

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel